|
JPS5612114B2
(https=)
|
1974-06-07 |
1981-03-18 |
|
|
|
US4231938A
(en)
|
1979-06-15 |
1980-11-04 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
|
US4444784A
(en)
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
DK149080C
(da)
|
1980-06-06 |
1986-07-28 |
Sankyo Co |
Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
|
|
US4450171A
(en)
|
1980-08-05 |
1984-05-22 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
US4448784A
(en)
|
1982-04-12 |
1984-05-15 |
Hoechst-Roussel Pharmaceuticals, Inc. |
1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
|
|
US4739073A
(en)
|
1983-11-04 |
1988-04-19 |
Sandoz Pharmaceuticals Corp. |
Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
|
|
US4681893A
(en)
|
1986-05-30 |
1987-07-21 |
Warner-Lambert Company |
Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
|
|
US4915954A
(en)
|
1987-09-03 |
1990-04-10 |
Alza Corporation |
Dosage form for delivering a drug at two different rates
|
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
US5316765A
(en)
|
1989-09-07 |
1994-05-31 |
Karl Folkers Foundation For Biomedical And Clinical Research |
Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
|
|
EP0633943A4
(en)
|
1992-04-03 |
1997-05-02 |
Alexander T Young |
GENTHERAPY USING TARGETED VIRAL VECTORS.
|
|
DE4309553A1
(de)
|
1993-03-24 |
1994-09-29 |
Bayer Ag |
Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
|
|
AU682253B2
(en)
|
1994-01-28 |
1997-09-25 |
Immunex Corporation |
CD 69 transcriptional regulatory elements
|
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
GB0028429D0
(en)
|
2000-11-22 |
2001-01-10 |
Astrazeneca Ab |
Therapy
|
|
GB0114533D0
(en)
|
2001-06-14 |
2001-08-08 |
Avidex Ltd |
Substances
|
|
GB0218781D0
(en)
|
2002-08-13 |
2002-09-18 |
Astrazeneca Ab |
Chemical process
|
|
US20050042217A1
(en)
|
2003-03-19 |
2005-02-24 |
Yan Qi |
Specific inhibition of allorejection
|
|
WO2010042490A1
(en)
*
|
2008-10-06 |
2010-04-15 |
Boston Medical Center Corporation |
A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
|
|
US20120064100A1
(en)
|
2009-03-18 |
2012-03-15 |
Simon Barry |
Biomarkers and uses thereof
|
|
US9840695B2
(en)
|
2009-04-28 |
2017-12-12 |
Agriculture Victoria Services Pty Ltd |
Plant technology
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
ES2602743T3
(es)
|
2010-09-08 |
2017-02-22 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Receptores de antígenos quiméricos con una región bisagra optimizada
|
|
EP2931893A1
(en)
|
2012-12-13 |
2015-10-21 |
Universität Leipzig |
T-cell modulation by exon skipping
|
|
EP4166148B1
(en)
|
2014-06-06 |
2026-02-18 |
Memorial Sloan-Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
|
US10975137B2
(en)
|
2014-11-06 |
2021-04-13 |
University Of Maryland, Baltimore |
CD8a and t cell receptor variants and methods of using same in modulating immune cell responses
|
|
GB201423361D0
(en)
|
2014-12-30 |
2015-02-11 |
Immatics Biotechnologies Gmbh |
Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
|
|
GB201504502D0
(en)
|
2015-03-17 |
2015-04-29 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
|
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
GB201510771D0
(en)
|
2015-06-19 |
2015-08-05 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
|
|
GB201511191D0
(en)
|
2015-06-25 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
T-cell epitopes for the immunotherapy of myeloma
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
GB201511792D0
(en)
|
2015-07-06 |
2015-08-19 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
|
|
MY189596A
(en)
|
2015-07-15 |
2022-02-18 |
Immatics Biotechnologies Gmbh |
A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
US10335471B2
(en)
|
2015-08-28 |
2019-07-02 |
Immatics Biotechnologies Gmbh |
Method for treating cancer with activated T cells
|
|
CN108513576A
(zh)
|
2015-09-14 |
2018-09-07 |
高山免疫科学股份有限公司 |
可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
|
|
GB201517538D0
(en)
|
2015-10-05 |
2015-11-18 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
|
|
HK1258444A1
(zh)
|
2015-10-09 |
2019-11-15 |
Immatics Biotechnologies Gmbh |
抗wt1/hla特异性抗体
|
|
JP7123794B2
(ja)
|
2015-12-09 |
2022-08-23 |
メモリアル スローン ケタリング キャンサー センター |
免疫細胞組成物及びそれを使用する方法
|
|
GB201521746D0
(en)
|
2015-12-10 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
|
|
GB201521894D0
(en)
|
2015-12-11 |
2016-01-27 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against various cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
GB201603568D0
(en)
|
2016-03-01 |
2016-04-13 |
Immatics Biotechnologies Gmbh |
Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
GB201604492D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
GB201604494D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
|
|
CN116731156A
(zh)
|
2016-03-16 |
2023-09-12 |
伊玛提克斯生物技术有限公司 |
用于癌症免疫治疗的转染t细胞和t细胞受体
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CA3032838A1
(en)
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
ZA201900664B
(en)
|
2016-08-17 |
2021-09-29 |
Paul Ehrlich Strasse 15 Tuebingen 72076 Germany |
T cell receptors and immune therapy using the same
|
|
DE102016115246C5
(de)
|
2016-08-17 |
2018-12-20 |
Immatics Biotechnologies Gmbh |
Neue t-zellrezeptoren und deren verwendung in immuntherapie
|
|
CN109996868A
(zh)
*
|
2016-09-23 |
2019-07-09 |
弗雷德哈钦森癌症研究中心 |
特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
|
|
EP3300863B1
(en)
|
2016-09-28 |
2020-06-17 |
Braun GmbH |
Electric shaver
|
|
DE102016123847B3
(de)
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
DE102016123859B3
(de)
|
2016-12-08 |
2018-03-01 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
KR20240007775A
(ko)
|
2016-12-08 |
2024-01-16 |
이매틱스 바이오테크놀로지스 게엠베하 |
T 세포 수용체 및 이를 사용하는 면역 요법
|
|
DE102016123893A1
(de)
|
2016-12-08 |
2018-06-14 |
Immatics Biotechnologies Gmbh |
T-Zellrezeptoren mit verbesserter Bindung
|
|
US20190359678A1
(en)
|
2017-02-09 |
2019-11-28 |
The Regents Of The University Of California |
Chimeric t cell antigen receptors and methods of use thereof
|
|
US11236145B2
(en)
|
2017-03-23 |
2022-02-01 |
Immatics Biotechnologies Gmbh |
T cell receptors and immune therapy using the same against PRAME positive cancers
|
|
DE102017106305A1
(de)
*
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
|
EA201992416A1
(ru)
|
2017-04-10 |
2020-02-25 |
Имматикс Байотекнолоджиз Гмбх |
Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
|
|
WO2018189148A1
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
US11235004B2
(en)
*
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
|
DE102017114737A1
(de)
|
2017-06-30 |
2019-01-03 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
LT3428194T
(lt)
|
2017-07-14 |
2021-12-10 |
Immatics Biotechnologies Gmbh |
Pagerinta dvejopo savitumo polipeptido molekulė
|
|
JP2020537515A
(ja)
|
2017-10-03 |
2020-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｈｐｖ特異的結合分子
|
|
US11008556B2
(en)
|
2017-10-12 |
2021-05-18 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
|
|
KR20250052472A
(ko)
|
2017-11-06 |
2025-04-18 |
이매틱스 바이오테크놀로지스 게엠베하 |
신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
|
|
BR112020016176A2
(pt)
|
2018-02-09 |
2022-02-22 |
Immatics Us Inc |
Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
CA3097396A1
(en)
*
|
2018-04-19 |
2019-10-24 |
Baylor College Of Medicine |
Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
|
|
WO2020049496A1
(en)
|
2018-09-05 |
2020-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
T cell modification
|